Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb 6:2:193-202.
doi: 10.2147/dddt.s4146.

Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies

Nathan W Kopper  1 , Jennifer Gudeman, Daniel J Thompson
Affiliations

Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies

Nathan W Kopper et al. Drug Des Devel Ther. .

Abstract

Vasomotor symptoms (VMS) associated with menopause can cause significant discomfort and decrease the quality of life for women in the peri-menopausal and post-menopausal stages of life. Hormone therapy (HT) is the mainstay of treatment for menopausal symptoms and is currently the only therapy proven effective for VMS. Numerous HT options are available to treat VMS, including estrogen-only and estrogen-progestogen combination products to meet the needs of both hysterectomized and nonhysterectomized women. In addition to selecting an appropriate estrogen or estrogen-progestogen combination, consideration should be given to the route of administration to best suit the needs of the patient. Delivery systems for hormone therapy include oral tablets, transdermal patches, transdermal topical (nonpatch) products, and intravaginal preparations. Oral is currently the most commonly utilized route of administration in the United States. However, evidence suggests that oral delivery may lead to some undesirable physiologic effects caused by significant gut and hepatic metabolism. Transdermal drug delivery may mitigate some of these effects by avoiding gut and hepatic first-pass metabolism. Advantages of transdermal delivery include the ability to administer unmetabolized estradiol directly to the blood stream, administration of lower doses compared to oral products, and minimal stimulation of hepatic protein production. Several estradiol transdermal delivery technologies are available, including various types of patches, topical gels, and a transdermal spray.

Keywords: estradiol; hormone therapy; menopause; transdermal drug delivery; vasomotor symptoms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of thrombosis risk in women with thrombotic mutations receiving HT. Abbreviation: HT, hormone therapy.
Figure 2
Figure 2
Mean (±SD) serum estradiol concentrations on day 14 following topical application for 14 days of one, two, or three sprays of Evamist (unadjusted for baseline). Evamist™ Prescribing Information. Ther-Rx Corporation, St. Louis, Missouri, USA. January 2008.
See this image and copyright information in PMC

References

    1. Abbas A, Fadel PJ, Want Z, et al. Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in post-menopausal women. Arterioscler Thromb Vasc Biol. 2004;24:e164–67. - PubMed
    1. ACOG Task Force on Hormone Therapy. Hormone therapy. Obstet Gynecol. 2004;104(suppl):1s–131s. - PubMed
    1. [AACE] American Association of Clinical Endocrinologists. AACE medical guidelines for clinical practice for management of menopause. Endocrinol Pract. 2006;12:315–37. - PubMed
    1. Anderson GL, Limacher M, Assaf AR, et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12. - PubMed
    1. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol. 2001;184:255–63. - PubMed